DURHAM, N.C., June 30, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that results from U.S. Navy studies demonstrated decreased mortality in porcine animal models that were given an intravenous dose of Oxycyte® perfluorocarbon emulsion (PFCE) after the onset of decompression sickness (DCS). These results showed a statistically significant decrease in mortality compared with the control group that did not receive Oxycyte PFCE. This data was published in the June issue of Aviation Space and Environmental Medicine. The authors of the paper are Drs. Richard T. Mahon, Tomas T. Watanabe and Charles R. Auker and Madison C. Wilson, all of the Undersea Medicine Department at the U.S. Naval Medical Research Center. Their work was funded by the Office of Naval Research.
